Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma

  • Soriano, Aroa|||0000-0001-9659-1471
  • Masanas, Marc|||0000-0002-2249-8554
  • Boloix, Ariadna|||0000-0002-1648-5589
  • Masiá, Núria
  • París-Coderch, Laia|||0000-0003-2145-5752
  • Piskareva, Olga
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Henrich, Kai-Oliver
  • Roma, Josep|||0000-0001-7692-6123
  • Westermann, Frank
  • Stallings, Raymond L.
  • Sábado, Constantino|||0000-0003-3956-5466
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
The online version of this article (10.1007/s00018-019-03041-4) contains supplementary material, which is available to authorized users., Current therapies for most non-infectious diseases are directed at or affect functionality of the human translated genome, barely 2% of all genetic information. By contrast, the therapeutic potential of targeting the transcriptome, ~ 70% of the genome, remains largely unexplored. RNA therapeutics is an emerging field that widens the range of druggable targets and includes elements such as microRNA. Here, we sought to screen for microRNA with tumor-suppressive functions in neuro-blastoma, an aggressive pediatric tumor of the sympathetic nervous system that requires the development of new therapies. We found miR-323a-5p and miR-342-5p to be capable of reducing cell proliferation in multiple neuroblastoma cell lines in vitro and in vivo, thereby providing a proof of concept for miRNA-based therapies for neuroblastoma. Furthermore, the combined inhibition of the direct identified targets such as CCND1, CHAF1A, INCENP and BCL-XL could reveal new vulnerabilities of high-risk neuroblastoma.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long Non-coding RNA PVT1 as a Prognostic and Therapeutic Target in Pediatric Cancer

  • Boloix, Ariadna|||0000-0002-1648-5589
  • Masanas, Marc|||0000-0002-2249-8554
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Antonelli, Roberta|||0000-0001-6884-7847
  • Soriano, Aroa|||0000-0001-9659-1471
  • Roma, Josep|||0000-0001-7692-6123
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
In recent decades, biomedical research has focused on understanding the functionality of the human translated genome, which represents a minor part of all genetic information transcribed from the human genome. However, researchers have become aware of the importance of non-coding RNA species that constitute the vast majority of the transcriptome. In addition to their crucial role in tissue development and homeostasis, mounting evidence shows non-coding RNA to be deregulated and functionally contributing to the development and progression of different types of human disease including cancer both in adults and children. Small non-coding RNAs (i.e., microRNA) are in the vanguard of clinical research which revealed that RNA could be used as disease biomarkers or new therapeutic targets. Furthermore, many more expectations have been raised for long non-coding RNAs, by far the largest fraction of non-coding transcripts, and still fewer findings have been translated into clinical applications. In this review, we center on PVT1, a large and complex long non-coding RNA that usually confers oncogenic properties on different tumor types. We focus on the compilation of early advances in the field of pediatric tumors which often lags behind clinical improvements in adult tumors, and provide a rationale to continue studying PVT1 as a possible functional contributor to pediatric malignancies and as a potential prognostic marker or therapeutic target.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

FAIM Is Regulated by MiR-206, MiR-1-3p and MiR-133b

  • Coccia, Elena|||0000-0002-9849-2423
  • Masanas, Marc|||0000-0002-2249-8554
  • López-Soriano, Joaquín
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Comella i Carnicé, Joan Xavier|||0000-0002-6218-0786
  • Pérez-García, M. Jose|||0000-0001-9014-7986
Apoptosis plays an important role during development, control of tissue homeostasis and in pathological contexts. Apoptosis is executed mainly through the intrinsic pathway or the death receptor pathway, i.e., extrinsic pathway. These processes are tightly controlled by positive and negative regulators that dictate pro- or anti-apoptotic death receptor signaling. One of these regulators is the Fas Apoptotic Inhibitory Molecule (FAIM). This death receptor antagonist has two main isoforms, FAIM-S (short) which is the ubiquitously expressed, and a longer isoform, FAIM-L (long), which is mainly expressed in the nervous system. Despite its role as a death receptor antagonist, FAIM also participates in cell death-independent processes such as nerve growth factor-induced neuritogenesis or synaptic transmission. Moreover, FAIM isoforms have been implicated in blocking the formation of protein aggregates under stress conditions or de-regulated in certain pathologies such as Alzheimer's and Parkinson's diseases. Despite the role of FAIM in physiological and pathological processes, little is known about the molecular mechanisms involved in the regulation of its expression. Here, we seek to investigate the post-transcriptional regulation of FAIM isoforms by microRNAs (miRNAs). We found that miR-206, miR-1-3p, and miR-133b are direct regulators of FAIM expression. These findings provide new insights into the regulation of FAIM and may provide new opportunities for therapeutic intervention in diseases in which the expression of FAIM is altered.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Novel KIF1A Missense Variant (R169T) Strongly Reduces Microtubule Stimulated ATPase Activity and Is Associated With NESCAV Syndrome

  • Aguilera, Cinthia|||0000-0002-0363-8590
  • Hümmer, Stefan|||0000-0002-8184-3872
  • Masanas, Marc|||0000-0002-2249-8554
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Guitart, Maria|||0000-0003-2957-7404
  • Jeyaprakash, A. Arockia
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Ruiz, Anna|||0000-0001-7314-5962
KIF1A is a microtubule-dependent motor protein responsible for fast anterograde transport of synaptic vesicle precursors in neurons. Pathogenic variants in KIF1A have been associated with a wide spectrum of neurological disorders. Here, we report a patient presenting a severe neurodevelopmental disorder carrying a novel de novo missense variant p.Arg169Thr (R169T) in the KIF1A motor domain. The clinical features present in our patient match with those reported for NESCAV syndrome including severe developmental delay, spastic paraparesis, motor sensory neuropathy, bilateral optic nerve atrophy, progressive cerebellar atrophy, epilepsy, ataxia, and hypotonia. Here, we demonstrate that the microtubule-stimulated ATPase activity of the KIF1A is strongly reduced in the motor domain of the R169T variant. Supporting this, in silico structural modeling suggests that this variant impairs the interaction of the KIF1A motor domain with microtubules. The characterization of the molecular effect of the R169T variant on the KIF1A protein together with the presence of the typical clinical features indicates its causal pathogenic effect.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

  • Masanas, Marc|||0000-0002-2249-8554
  • Masiá, Nuria|||0000-0002-8352-2327
  • Suárez, Leticia|||0000-0002-3864-4616
  • Olivan, Mireia|||0000-0002-8464-0827
  • Soriano, Aroa|||0000-0001-9659-1471
  • Majem Cavaller, Blanca|||0000-0003-3613-0432
  • Devis-Jauregui, Laura|||0000-0003-3736-3983
  • Burgos-Panadero, Rebeca
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Rodriguez-Sodupe, Pau
  • Boloix, Ariadna|||0000-0002-1648-5589
  • Toledano, Ignasi|||0000-0003-0880-8904
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Navarro, Alexandra
  • Llobet Navas, David|||0000-0003-1443-7003
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Roma, Josep|||0000-0001-7692-6123
  • Noguera, Rosa
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Krauss, Rolf
  • Gallego, Soledad|||0000-0002-4712-9624
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Segura, Miguel F.|||0000-0003-0916-3618